Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study.

Lancet Reg Health Eur · 2023 · PMC9932646 · PMID 36817181

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significantno p-value reported

Overall a major PFS benefit (HR 0.46 (95% CI 0.37–0.57)) was found, but with a borderline significant OS benefit (HR 0.80 (95% CI 0.64–1.00)).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.